SAPOFEN Junior 100mg/5ml price in UAE

Overview

Welcome to Dwaey, specifically on SAPOFEN Junior 100mg/5ml Suspension page.
This medicine contains an important and useful components, as it consists of Ibuprofen.
SAPOFEN Junior 100mg/5ml is available in the market in concentration 100mg/5ml and in the form of Suspension.

SPIMACO (AL QASSIM PHARMACEUTICAL PLANT) is the producer of SAPOFEN Junior 100mg/5ml and it is imported from SAUDI ARABIA, The most popular alternatives of SAPOFEN Junior 100mg/5ml are listed downward .

Mode Of Action

Ibuprofen inhibits synthesis of prostaglandins in body tissues by inhibiting cyclooxygenase-1 and 2. It has anti-inflammatory, analgesic and antipyretic properties.

Indication

Rheumatoid arthritis
Osteoarthritis
Pain
Fever
Pericarditis
Dysmenorrhea
Patent ductus arteriosus
Inflammation
Musculoskeletal and joint disorders

Precaution

Asthma; renal or hepatic disorders; bleeding disorders; CV disease. Pregnancy, lactation. Lactation: Drug excreted into breast milk; use not recommended (American Academy of Pediatrics committee states that drug is compatible with nursing)

Side Effects

1-10% Dizziness (3-9%)
Epigastric pain (3-9%)
Heartburn (3-9%)
Constipation (1-3%)
Nausea (3-9%)
Rash (3-9%)
Tinnitus (3-9%)
Edema (1-3%)
Fluid retention (1-3%)
Headache (1-3%)
Vomiting (1-3%) <1% Acute renal failure (sometimes with acute tubular necrosis or hyperkalemia
polyuria
azotemia
cystitis
hematuria
decreased creatinine clearance
elevations in blood urea nitrogen (BUN) or creatinine without other manifestations of renal failure) Agranulocytosis
Aplastic anemia
Erythema multiforme
Erythematous macular rashes
Exfoliative dermatitis
Hemolytic anemia (with or without positive direct antiglobulin test results)
Neutropenia
Thrombocytopenia (with or without purpura)
Toxic epidermal necrolysis (Lyell syndrome) and photosensitivity reactions Potentially Fatal: Severe CV thrombotic events. Severe GI bleeding
ulceration and perforation.

Contra indication

Active peptic ulcer; hypersensitivity. Neonates with congenital heart disease, suspected necrotising enterocolitis and active bleeding (parenteral).

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Pregnancy category: C; D in 3rd trimester or near delivery. At >30 weeks' gestation; may cause premature closure of ductus arteriosus

Interaction

Increased risk of GI bleeding w/ warfarin, corticosteroids, SSRIs and aspirin. May reduce the natriuretic effects of diuretics. Reduced antihypertensive effect of ACE inhibitors and angiotensin II receptor antagonists. May increase toxicity of lithium and methotrexate. Increased nephrotoxicity w/ ciclosporin and tacrolimus.